Paul Wilton

Working with change, not against it
Change happens: markets conditions change; competitors change; supply, demand,
technologies, cultures, people - all change. Successful organisations are those
able to respond to change timely and effectively, turning risk into
opportunity.  For business to implement and execute on an effective technical
strategy, the ability to adapt to new conditions is the key to success.  We
specialise in evolutionary design, a powerful approach to technical strategy
that enables organisations to gain business advantage through fast reaction to
market changes.

Whatever the state and history of your technical function, it should never hold
back your business vision. Technology should enable and exploit opportunities,
not jeopardise your first-mover advantage or get in the way of on your
commercial strategy. If you feel your technical estate is making you miss out on
business opportunities then give us a call. We can help.

How we can help
We have helped customers from start-ups to bluechip multionationals implement
strategies which have delivered ambitious business plans and enabled them to
exploit new commercial opportunities. That ability to innovate and evolve has
been shaped through:

 * A deep, shared understanding of the business domain
 * A dogged commercial focus on core market differentiators
 * Anchoring everything against customer needs
 * Mapping evolutionary trends in the technologies that support those needs
 * Relentless technological focus on simplicity
 * Rigorous technology risk management
 * Lean processes for agile governance

Expert Technical Strategy

Matt Shearer

Like most technology decisions, the solution choice should be made only when you
have a clear understanding of the problem you are solving and what your user’s
needs are, otherwise you may make an expensive mistake.

Not all graph databases are equal
There are a broad selection of graph database features to choose from, and your
choice will have fundamental impacts on your capability to deliver your business
requirements now and in the future.

These are some of the areas you will need to explore:-

 1. Which underlying graph technology lends itself best to your primary use case
    - RDF graph, or Labelled-Property graph?
 2. Do you need to use "reasoning"?
 3. What are your scaling requirements?
 4. How do you and your systems need to interact with your knowledge graph?
 5. Is full-text search important?

Explore your primary use case
At Data Language we have extensive experience in graph technologies and can help
you make all the right choices.

We use a collaborative approach to establishing customer graph database
requirements, and we pride ourselves on being vendor-neutral and independent.

Get in touch - we can help you through the exploratory process.

Choosing the right graph database

Julian Everett

Over the past five years it has been our privilege to be a technology partner of 
Cochrane [https://www.cochrane.org/]. For anyone unfamiliar with their work,
they are globally recognised as the gold standard in evidence-based healthcare.
Historically their primary published output has been systematic reviews, which
evaluate and summarise the current state of human knowledge about specific
clinical questions. These then inform both healthcare policy and clinical
guidelines for point-of-care decision making around the world. For example, over
90% of WHO guidelines are informed by Cochrane reviews. 

The review production process starts with the formalisation of the clinical
question of interest in terms of the Population it relates to (e.g. age, sex,
condition), the Interventions being investigated (e.g. drugs and/or procedures),
the Comparators against which the Interventions are being evaluated (e.g.
placebo), and the Outcomes against which effects are measured. This is then
translated into search protocol and run against trial registries and journal
databases to identify all relevant clinical study information in the public
domain. The matches are then evaluated for risk of bias, and the subset of
results which meet Cochrane’s stringent data quality thresholds are subsequently
aggregated and analysed to determine the cumulative effect estimates. 

In essence, this is about the identification of causal relationships between
interventions and outcomes. To that end, up until now Cochrane has focussed on
double-blind randomised controlled trials. They provide the highest quality
input data: randomisation greatly reduces the likelihood of alternative
explanations for the observed results as the number of participants increases;
blinding of field researchers and participants (i.e. hiding information about
specific interventions) removes the cognitive and behavioural bias risks that
might arise if, for example, placebos are known. 

Finally, review production is not a static process. New information is being
released into the public domain all the time both in the form of additional
journal articles about completed studies as well as information about new
studies. As a result, ongoing evidence surveillance and timely meta-analysis
updates are important additional requirements.

During our time working with Cochrane, we have built a new data platform using
domain-driven design techniques which has an explicit information model encoded
into a knowledge graph at its core. The model is published here
[https://data.cochrane.org/ontologies/]. This is complemented by a loosely
coupled, service-based architecture which ensures each business capability in
the value stream is cohesively encapsulated. In a follow up article, my
colleague Paul Wilton will review how the technical architecture hangs together
[https://datalanguage.com/blog/how-knowledge-graph-technology-is-helping-cochrane-respond-to-covid-19]
. The platform design allows services to be very quickly deployed in new
choreographies as the business context changes - something which has proved
invaluable over the last few weeks. 

So, what have been the business function and information flow impacts of the
Covid-19 pandemic on Cochrane? Firstly it has created an unprecedented critical
demand for the most up-to-date, reliable evidence to inform frontline clinical
decision-making around the world in order to save as many lives as possible. To
that end, they have been asked by the WHO to produce a precisely scoped,
authoritative register of Covid-19 studies. This essentially inverts their
business model from one based on a wide coverage of clinical questions using
only the highest quality primary evidence to one based on a single clinical
question which urgently extracts every bit of informational value from every
piece of evidence available. That means using all types of RCTs and
interventional studies, as well as observational studies, modelling studies,
diagnostic/prognostic studies and anything else that might improve outcomes. The
surveillance requirement for updates and new evidence switched from months to
days. The cycle time for systematic review production needed to be cut, and a
new Rapid Review format has been developed as a result to ensure baseline
datasets can be pulled together as quickly as possible and then augmented with
streamlined editorial content to meet clinical need. At the same time, the
feedback loop to frontline workers was closed to ensure that their highest
priority clinical questions are the ones being addressed first.

The Covid-19 Study Register [https://covid-19.cochrane.org/] was launched
internally on Monday 30th March and publicly on Monday 6th April. In all, two
back-end platforms were integrated together and a new front-end web application
was designed, built and shipped in just under 3 weeks. It has necessarily been
our fastest ever delivery by some distance, and was only even remotely possible
because of three core enablers:

 1. A data architecture, technical architecture and continuous integration
    infrastructure which minimised the technical risks and impacts of adapting
    to the changing organisational context.
 2. A small number of individually, amazingly talented developers.
 3. The tacit/emergent team structure and pre-existing relationships between
    those developers, established over a long track record of successful
    delivery on other demanding client projects, which meant that as a delivery
    unit they functioned at a truly optimal level from day one.

Since internal launch, our focus has been on getting as much data as possible
into the information model by any and every means we can think of, as quickly as
possible and at the highest possible quality levels. This is covering expert
crowd annotation, machine learning, and other text analysis and informational
reverse engineering techniques. One of the biggest automation/ML challenges
currently is the lack of training data due to the rapid emergence and rate of
evolution of the Covid-19 domain. We have previous experience of this class of
problem from our work with media newsrooms and automated classification of
breaking news stories. It is likely the crisis will drive extensive further
innovation in this space. 

At the same time, we have started receiving comments from stakeholders and end
users across the organisation. It has been some of the most inspiring and
touching feedback we have ever received both as an organisation and as
individuals, especially in light of the wider situation right now. The high
point so far was one very senior Cochrane staff member who, in wonderfully
memorable terms, said he couldn't overstate how useful the register is to all
aspects of his work and that he's now going to shout about it to everyone who
will listen.

A beautiful moment in the midst of demanding times.

Technical Strategy

Our Technical Strategy work

Technical Strategy Blog Posts